Effects of an ageing population and the replacement of immune birth cohorts on the burden of hepatitis A in the Netherlands

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  McDonald, Scott A ^a   Mangen, Marie Josée J ^b   Suijkerbuijk, Anita ^a   Colzani, Edoardo ^c   Kretzschmar, Mirjam E E ^a,b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

Author keywords

Disability adjusted life years; Dynamic transmission model; Hepatitis A virus; Natural immunity; Population ageing

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NONHUMAN; OUTCOME ASSESSMENT; POPULATION DYNAMICS; PREDICTION; PRESCHOOL CHILD; QUALITATIVE ANALYSIS; QUALITY ADJUSTED LIFE YEAR; SCHOOL CHILD; TREND STUDY; VIRUS IDENTIFICATION; VIRUS LOAD; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS A; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MODELS, STATISTICAL; NETHERLANDS; PREVALENCE; YOUNG ADULT;

EID: 84874474963     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-120     Document Type: Article

References (31)

1. Verhoef L, Boot HJ, Koopmans M, Mollema L, Van Der Klis F, Reimerink J, Van Pelt W. Changing risk profile of hepatitis A in The Netherlands: a comparison of seroprevalence in 1995-1996 and 2006-2007. Epidemiol Infect 2011, 139(8):1172-1180. 10.1017/S0950268810003043, 21226987.
2. Gust ID, Lehmann NI, Lucas CR. Relationship between prevalence of antibody to hepatitis A antigen and age: a cohort effect?. J Infect Dis 1978, 138(3):425-426. 10.1093/infdis/138.3.425, 212492.
3. Schenzle D, Dietz K, Frosner GG. Antibody against hepatitis A in seven European countries. II. Statistical analysis of cross-sectional surveys. Am J Epidemiol 1979, 110(1):70-76.
4. Jacobs RJ, Gibson GA, Meyerhoff AS. Cost-effectiveness of hepatitis A-B vaccine versus hepatitis B vaccine for healthcare and public safety workers in the western United States. Infect Control Hosp Epidemiol 2004, 25(7):563-569. 10.1086/502440, 15301028.
5. Termorshuizen F, Dorigo-Zetsma JW, de Melker HE, van den Hof S, Conyn-Van Spaendonck MA. The prevalence of antibodies to hepatitis A virus and its determinants in The Netherlands: a population-based survey. Epidemiol Infect 2000, 124(3):459-466. 10.1017/S0950268899003842, 2810932, 10982070.
6. Koff RS. Hepatitis A. Lancet 1998, 351(9116):1643-1649. 10.1016/S0140-6736(98)01304-X, 9620732.
7. Havelaar AH, Haagsma JA, Mangen MJ, Kemmeren JM, Verhoef LP, Vijgen SM, Wilson M, Friesema IH, Kortbeek LM, van Duynhoven YT. Disease burden of foodborne pathogens in the Netherlands, 2009. Int J Food Microbiol 2012, 156(3):231-238. 10.1016/j.ijfoodmicro.2012.03.029, 22541392.
8. Van Der Eerden LJ, Bosman A, Van Duynhoven YT. Surveillance of hepatitis A in the Netherlands 1993-2002. Ned Tijdschr Geneeskd 2004, 148(28):1390-1394.
9. Suijkerbuijk AW, Lindeboom R, van Steenbergen JE, Sonder GJ, Doorduyn Y. Effect of hepatitis A vaccination programs for migrant children on the incidence of hepatitis A in The Netherlands. Eur J Public Health 2009, 19(3):240-244. 10.1093/eurpub/ckn145, 19174503.
10. Leach CT. Hepatitis A in the United States. Pediatr Infect Dis J 2004, 23(6):551-552. 10.1097/01.inf.0000130071.03003.c2, 15194837.
11. De Melker HE, Conyn-van Spaendonck MA. Immunosurveillance and the evaluation of national immunization programmes: a population-based approach. Epidemiol Infect 1998, 121(3):637-643. 10.1017/S0950268898001587, 2809572, 10030714.
12. van den Hof S, de Melker HE, Suijkerbuijk AWM, Conyn-van Spaendonck MAE. Pienter project: Description of serumbank and information on participants from the questionnaires. RIVM report no. 213675005 1998, RIVM: Bilthoven.
13. Lieberman JM, Chang SJ, Partridge S, Hollister JC, Kaplan KM, Jensen EH, Kuter B, Ward JI. Kinetics of maternal hepatitis a antibody decay in infants: implications for vaccine use. Pediatr Infect Dis J 2002, 21(4):347-348. 10.1097/00006454-200204000-00017, 12075769.
14. McDonald SA, van Lier EA, Plass D, Kretzschmar ME. The impact of demographic change on the estimated future burden of infectious diseases: Examples from hepatitis B and seasonal influenza in the Netherlands. BMC Pub Health 2012, 12:1046.
15. Leslie PH. The use of matrices in certain population mathematics. Biometrika 1945, 33(3):183-212. 10.1093/biomet/33.3.183, 21006835.
16. Kretzschmar ME, Mangen M-J, Pinheiro P, Jahn B, Fèvre EM, Longhi S, Lai T, Havelaar AH, Stein C, Cassini A. New methodology for estimating the burden of communicable diseases in Europe. PLoS Med 2012, 9(4):e1001205. 10.1371/journal.pmed.1001205, 3328443, 22529750.
17. Jacobs RJ, Margolis HS, Coleman PJ. The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates. Arch Pediatr Adolesc Med 2000, 154(8):763-770.
18. Srinivasa Rao AS, Chen MH, Pham BZ, Tricco AC, Gilca V, Duval B, Krahn MD, Bauch CT. Cohort effects in dynamic models and their impact on vaccination programmes: an example from hepatitis A. BMC Infect Dis 2006, 6:174. 10.1186/1471-2334-6-174, 1702544, 17147828.
19. Bauch CT, Anonychuk AM, Pham BZ, Gilca V, Duval B, Krahn MD. Cost-utility of universal hepatitis A vaccination in Canada. Vaccine 2007, 25(51):8536-8548. 10.1016/j.vaccine.2007.10.001, 17996339.
20. van Lier EA, Havelaar AH, Nanda A. The burden of infectious diseases in Europe: a pilot study. Euro Surveill 2007, 12(12):E3-4.
21. Murray CJL, Lopez AD. The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020 (Global burden of disease and injuries series; I) 1996, Cambridge (MA): Harvard School of Public Health on behalf of the World Health Organization and the World Bank.
22. Haagsma JA, van der Zanden BP, Tariq L, van Pelt W, van Duynhoven YTPH, Havelaar AH. Disease burden and costs of selected foodborne pathogens in the Netherlands, 2006 2009, Bilthoven: National Institute for Public Health and the Environment.
23. McKay M, Beckman R, Conover WA. Comparison of three methods for selecting values of input variables in the analysis of output from a computer code. Technometrics 1979, 21(2):239-245.
24. R Development Core Team R: A Language and Environment for Statistical Computing 2011, Vienna, Austria: R Foundation for Statistical Computing, R Development Core Team.
25. Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics 2002, 109(5):839-845. 10.1542/peds.109.5.839, 11986444.
26. Termorshuizen F, van de Laar MJ. The epidemiology of hepatitis A in the Netherlands, 1957-1998. Ned Tijdschr Geneeskd 1998, 142(43):2364-2368.
27. Reintjes R, Bosman A, de Zwart O, Stevens M, van der Knaap L, van den Hoek K. Outbreak of hepatitis A in Rotterdam associated with visits to 'darkrooms' in gay bars. Commun Dis Public Health 1999, 2(1):43-46.
28. Bauch CT, Rao AS, Pham BZ, Krahn M, Gilca V, Duval B, Chen MH, Tricco AC. A dynamic model for assessing universal Hepatitis A vaccination in Canada. Vaccine 2007, 25(10):1719-1726. 10.1016/j.vaccine.2006.11.020, 17229493.
29. Friesema IHM, de Jong AEI, van Pelt W. Meldingen van voedselinfecties en -vergiftigingen in 2009 en 2010. Infectieziekte Bulletin 2012, 23(2):47-52.
30. Baaten GG, Sonder GJ, van der Loeff MF, Coutinho RA, van den Hoek A. Fecal-orally transmitted diseases among travelers are decreasing due to better hygienic standards at travel destination. J Travel Med 2010, 17(5):322-328. 10.1111/j.1708-8305.2010.00442.x, 20920053.
31. Suijkerbuijk AW, Lugner A, van Pelt W, Wallinga J, Verhoef L, de Melker HE, de Wit A. Assessing potential introduction of universal or targetted hepatitis A vaccination in the Netherlands. Vaccine 2012, 30(35):5199-5205. 10.1016/j.vaccine.2012.06.014, 22721900.